FDA approves new nail fungus treatment

June 12, 2014
FDA approves new nail fungus treatment

(HealthDay)—A new topical nail fungus treatment, Jublia, has been approved by the U.S. Food and Drug Administration.

Jublia (efinaconazole) is made by the Canadian company Valeant Pharmaceuticals International Inc., the Associated Press reported Wednesday.

Jublia comes in liquid form and is applied directly to the nail. According to Valeant, FDA approval was based on two studies involving more than 1,600 people with onychomycosis. The findings were published last year in the Journal of the American Academy of Dermatology. Cure rates were about 18 percent for the patients involved in one study, and about 15 percent for those involved in the other.

In a statement, Valeant said it plans to begin marketing Jublia late in 2014.

More information: Health Highlights: June 11, 2014

Related Stories

Valeant raises cash-stock offer for Allergan (Update)

May 28, 2014

Valeant Pharmaceuticals has pumped more cash into its bid for Botox maker Allergan, and it also defended its business model on Wednesday, a day after its reluctant acquisition target aired more concerns about a deal.

Recommended for you

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

carllvsports
not rated yet Aug 09, 2014
Very interesting! I hope this approach can be rolled out into market as soon as possible, and then I'll give it a shot. I have tried tons of ways to deal with this infection, but none of them seemed really effective for me. Vinegar, tea oil, oral medications can only ease the symptoms, but was never able to kill the bacteria. I'm considering taking a laser treatment, but I'm not sure about the real effect. I got some information from here: http://lasernail therapy.com. Is there anyone who had this kind of treatment before? Thanks for advice.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.